Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.2129 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2094 | 0.9815 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2094 | 0.9815 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.1257 | 0.5508 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2129 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.2094 | 0.9815 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.1257 | 0.5508 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1257 | 0.5508 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.2129 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2129 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1257 | 0.5508 | 0.5 |
Onchocerca volvulus | 0.2129 | 1 | 0.5 | |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2129 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2129 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2094 | 0.9815 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.2094 | 0.9815 | 0.9604 |
Loa Loa (eye worm) | hypothetical protein | 0.2129 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.1257 | 0.5508 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 70.5 umol/L | Antiproliferative activity against human A549 cells assessed as cell viability after 72 hrs by MTT assay | ChEMBL. | 24012378 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.